E. Wu

Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

M. Sliwkowski, R. Scheller, S. Spencer, 2014, Journal of medicinal chemistry.

Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform.

J. Suh, M. J. Brun, M. Ho, 2019, Journal of controlled release : official journal of the Controlled Release Society.